Five years after my lymphoma diagnosis, life looks normal on the outside; however, the fear of recurrence and the reality of ...

A prominent example is chromosomal translocation, with the IGH-BCL2 translocation being the most frequently observed in follicular lymphoma. This translocation leads to BCL2 gene overexpression under ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in combination therapy.

CHICAGO — In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor ...

In July 2020, Monjuvi in combination with lenalidomide received FDA approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise ...

The FDA approved tafasitamab (Monjuvi; Incyte) for patients with relapsed or refractory follicular lymphoma in combination with the immunomodulatory imide drug lenalidomide and the anti-CD20 mAb ...

Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival benefits in combination therapy.

The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory follicular lymphoma.